A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against .

Antibiotics are considered to be the first line of treatment for mild to moderately severe infection (CDI) in humans. However, antibiotics are also risk factors for CDI as they decrease colonization resistance against by altering the gut microbiota and metabolome. Finding compounds that selectively inhibit different stages of the life cycle, while sparing the indigenous gut microbiota is important for the development of alternatives to standard antibiotic treatment.

Control of Expression in via Autoregulation and a Master Repressor (MtrR) of a Drug Efflux Pump Operon.

The MtrCDE efflux pump of contributes to gonococcal resistance to a number of antibiotics used previously or currently in treatment of gonorrhea, as well as to host-derived antimicrobials that participate in innate defense. Overexpression of the MtrCDE efflux pump increases gonococcal survival and fitness during experimental lower genital tract infection of female mice. Transcription of can be repressed by the DNA-binding protein MtrR, which also acts as a global regulator of genes involved in important metabolic, physiologic, or regulatory processes.